Gefitinib Tablets

WARNINGS AND PRECAUTIONS

• This medication is not recommended for those females who`ve pregnant or have the intention to become pregnant.
• Gefitinib should be avoided during the time period of breastfeeding. It may be hazardous for the infant.
• Before taking Geftinat tablets, share your medical history with your physician specifically diseases related to the Liver.
• In order to detect the interaction of this medication, patients are advised to mark down all the products they use, be it is an over a counter, be it is a herbal product, be it is a prescription drug or be it is a non-prescription drug.
• In some patients asymptomatic increases in liver transaminases have been reported; therefore, periodic liver function (bilirubin, transaminases, and alkaline phosphatase) testing must be considered. Discontinuation or interruption of Geftinat should be considered if changes are severe.
• Patients should be advised to seek medical advice promptly if they develop) severe or persistent diarrhea, nausea, anorexia, or vomiting, as these have sometimes been associated with dehydration) an onset or worsening of pulmonary symptoms, ie, shortness of breath or cough) an eye irritation) any other new symptoms.
• Safety and effectiveness of this medication in pediatric patients have not been specified.
• Patients with severe renal impairment should be treated with caution when given Geftinat.
• Safety and efficacy of Gefitinib have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.
• Periodic liver function testing should be performed. Withhold Gefitinib in patients with worsening liver function and discontinue in patients with severe hepatic impairment.
• Geftinat treatment must be discontinued or interrupted if the patient develops , blistering, severe bullous or exfoliating conditions.
• Advise patients to immediately contact their healthcare provider for new onset or worsening of pulmonary symptoms such as dyspnea, cough and fever.
• Advise patients promptly to contact their healthcare provider if they develop eye symptoms, lacrimation, light sensitivity, blurred vision, eye pain, red eye or changes in vision.